Longer-term data raise prospects for Apellis’ pegcetacoplan
Apellis Pharma, blindness, complement therapeutics, Empaveli, geographic atrophy, ophthalmology, pegcetacoplan
0 Comment
blindness
Apellis reports mixed data with eye drug, but plans to file anyway
Apellis Pharma, blindness, complement therapeutics, Empaveli, geographic atrophy, ophthalmology
0 Comment
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug
Allergan, blindness, CRISPR/Cas9, Editas, gene editing, Leber’s Congenital Amaurosis, ophthalmology
0 Comment
Iveric rockets on mid-stage trial of Zimura in dry AMD
age-related macular degeneration, blindness, geographic atrophy, Iveric Bio, Zimura
0 Comment
Raising awareness of LHON for Rare Disease Day 2018
blindness, Leber's hereditary optic neuropathy, LHON, patients, rare disease
0 Comment
As Rare Disease Day approaches on 28 February, Santhera has created an infographic explaining the signs and symptoms of the rare disease Leber’s hereditary optic neuropathy (LHON), a progressive eye disease that results in blindness.
‘Bionic eye’ receives FDA fast-track review designation
blindness, digital health, fda, medical devices, Orion, Second Sight
0 Comment
Review of Second Sight’s Orion will now be streamlined.
Shedding light on LHON: the rare blindness affecting young adults
blindness, Leber's hereditary optic neuropathy, LHON, patients, rare disease
0 Comment
LHON is a frequently misdiagnosed condition that needs faster diagnosis.
Submission completed, Spark sets sight on first ever US gene therapy approval
blindness, cell and gene therapy, gene therapy, Spark Therapeutics, uniQure
0 Comment
Australian biotech gets $18 million for ‘bionic eye’
Bionic Vision Technologies, blindness, digital health, medical devices, retinitis pigmentosa
0 Comment
Company gains $18 million in funding.
1 2